 |
|
 |
| |
 |
|
|
| |
 |
Nikhil Munshi MD
Physician
Title: Physician to Waldenstrom’s and Multiple Myeloma
Specialty: Plasma Cell Disorders
Hospital: Dana-Farber Cancer Institute
Email: Nikhil_Munshi@dfci.harvard.edu
Address: 44 Binney Street, LG 102
Boston, MA 02115-6084
Phone: 617-632-5607
|
|
Dr. Munshi is an Associate Professor of Medicine at the Harvard Medical School, an Associate Director of the Jerome Lipper Myeloma Center at the Dana Farber Cancer Institute, an Associate Physician at Brigham and Women’s Hospital, and an Attending Physician at Boston VA Healthcare System, all in Boston, Massachusetts. Dr. Munshi is also the Chairman of the Expert Panel on Myeloma for the National VA Healthcare System and a member of the Subcommittee on Growth Factors for the American Society of Hematology.
He earned his bachelor of medicine/bachelor of surgery and medical degree in Internal Medicine from the Maharaja Sayajirao University of Baroda, India. His research fellowship in oncology was completed at Johns Hopkins Oncology Center in Baltimore, Maryland, and his haematology/oncology clinical fellowship was completed at Indiana University Medical Center in Indianapolis. Dr. Munshi joined the staff at the Myeloma Center at the University of Arkansas in 1992 in both research and clinical roles and was promoted to Professor of Medicine and Director of the Clinical Gene Transduction Laboratory at the Arkansas Cancer Research Center in July 2000.
Dr. Munshi's current research activities are centered around developing novel therapeutic modalities including immunotherapy/vaccine approaches and molecular strategies for myeloma and its translational applications to the clinic. Several promising immunobased therapies have been developed from Dr. Munshi’s research, including vaccines using fused myeloma cells and dendritic cells that focus the innate immune response against myeloma. Additionally, he is also the principle investigator on studies evaluating the effects of a VEGF-receptor inhibitor (an anti-angiogenic agent in relapsed myeloma) and the efficacy and biological effects of anti CD-40 antibody as a third-line therapy in myeloma. He has over 150 publications and book chapters, primarily in the field of Myeloma. His grant support is substantial and has included grants from National Institutes of Health, American Cancer Society and VA Research grants. He was awarded a Leukemia Society of America Scholar in Translational Research award. Dr. Munshi has been a member of numerous National Institutes of Health committees. |
<< Back
|
|
| |
|
|
